• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ProSomnus Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    3/22/24 4:15:27 PM ET
    $OSA
    Medical Specialities
    Health Care
    Get the next $OSA alert in real time by email
    false 0001934064 0001934064 2024-03-19 2024-03-19 0001934064 us-gaap:CommonStockMember 2024-03-19 2024-03-19 0001934064 osa:WarrantseachwholewarrantexercisableforoneshareofCommonStockMember 2024-03-19 2024-03-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 19, 2024

     

    PROSOMNUS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41567   88-2978216
    (State or other jurisdiction of
    incorporation)
      (Commission file number)   (IRS Employer Identification No.)

     

    5675 Gibraltar Dr.
    Pleasanton, CA
     94588
    (Address of principal executive offices) (Zip Code)

     

    (844) 537-5337

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  Trading
    Symbol
      Name of each exchange on
    which registered
    Common Stock, par value $0.0001 per share  OSA  The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share  OSAAW  The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 21, 2023, on September 18, 2023, ProSomnus, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it was no longer in compliance with the minimum Market Value of Publicly Held Shares (the “MVPHS”) of $15,000,000 required for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq afforded the Company an initial compliance period of 180 calendar days for the MVLS Requirement, which expired on March 18, 2024 (the “Compliance Date”).

     

    On March 19, 2024, the Company received a determination letter from the Staff that it had failed to regain compliance with the MVPHS Requirement by the Compliance Date because the Company’s MVPHS did not reach $15,000,000 by the Compliance Date.

     

    As previously disclosed on a Current Report on Form 8-K filed with the SEC on February 16, 2024, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s delisting determination for failing the meet the Market Value of Listed Securities Nasdaq listing requirement (the “MVLS Requirement”). Nasdaq notified the Company that such request had been granted and a hearing in front of the Panel had been scheduled. Accordingly, the Company plans to also present a compliance plan to regain compliance with the MVPHS Requirement in addition to a plan to regain compliance with the MVLS Requirement at such previously scheduled hearing in front of the Panel. There can be no assurance that the Panel will grant the Company’s request for continued listing.

     

    Additionally, as previously disclosed, the Company received a separate written notice from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Company was afforded an initial compliance period of 180 calendar days for the Minimum Bid Price Requirement, which is set to expire on April 30, 2024.

     

    The Company is pursuing resolution of the deficiencies noted; however, there can be no assurance that the Company’s plan as presented to the Panel will be accepted by the Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements, or that a Panel will stay the suspension of the Company’s securities. If the Company’s securities are delisted from the Nasdaq Global Market and Nasdaq Capital Market, it could be more difficult to buy or sell the Company’s securities or to obtain accurate quotations, and the price of the Company’s securities could suffer a material decline. Delisting could also impair the Company’s ability to raise capital and/or trigger defaults and penalties under outstanding agreements or securities of the Company.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern the proposed transaction and the Company’s expectations, strategy, plans or intentions regarding it. Forward-looking statements in this Current Report on Form 8-K include, but are not limited to, the Company’s intention to present a compliance plan to regain compliance with the MVPHS Requirement and MVLS Requirement to the Panel.

     

     

     

     

    All forward-looking statements included in this Current Report on Form 8-K are made as of the date of this report, based on information currently available to the Company, deal with future events, and are subject to various risks and uncertainties, including the risk that the Company may not meet the MVPHS Requirement, Minimum Bid Price Requirement or the MVLS Requirement by the required compliance date or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, and the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from the Company’s current expectations are more fully described in the Company’s Annual Report on Form 10-K filed with the SEC on April 14, 2023, any subsequently filed Quarterly Reports on Form 10-Q, and its other reports, each as filed with the SEC. Except as required by law, the Company assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 22, 2024 PROSOMNUS, INC.
       
      By: /s/ Brian B. Dow                 
      Name: Brian B. Dow
      Title: Chief Financial Officer

     

     

     

    Get the next $OSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kim Sung was granted 315,742 shares, increasing direct ownership by 157% to 516,808 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:20:29 PM ET
    $OSA
    Medical Specialities
    Health Care

    Dow Brian B was granted 315,742 shares, increasing direct ownership by 337% to 409,492 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:16:43 PM ET
    $OSA
    Medical Specialities
    Health Care

    Liptak Len was granted 1,322,756 shares, increasing direct ownership by 208% to 1,957,216 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:14:33 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

    PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin

    3/26/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

    PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv

    3/15/24 8:01:20 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

    PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. "This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus® RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory," commented L

    2/22/24 8:30:00 AM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    SEC Filings

    View All

    ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ProSomnus, Inc. (0001934064) (Filer)

    5/8/24 9:25:27 AM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ProSomnus, Inc. (0001934064) (Filer)

    4/30/24 4:51:50 PM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form 10-K/A filed by ProSomnus Inc. (Amendment)

    10-K/A - ProSomnus, Inc. (0001934064) (Filer)

    4/29/24 5:29:15 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Financials

    Live finance-specific insights

    View All

    ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

    PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin

    3/26/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

    PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv

    3/15/24 8:01:20 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

    PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth quarter and fiscal year 2023 financial results and provide a business update before market open on Monday, March 18, 2024 at the 36th Annual ROTH Conference and via a live webcast. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Following the call, management will participate in the 36th Annual ROTH Conference, being held March 17-19, 2024. Fourth Quarter and Fisc

    2/20/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ProSomnus Inc.

    SC 13G - ProSomnus, Inc. (0001934064) (Subject)

    2/14/24 11:10:52 AM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by ProSomnus Inc. (Amendment)

    SC 13G/A - ProSomnus, Inc. (0001934064) (Subject)

    2/12/24 11:46:53 AM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by ProSomnus Inc. (Amendment)

    SC 13D/A - ProSomnus, Inc. (0001934064) (Subject)

    12/8/23 4:15:31 PM ET
    $OSA
    Medical Specialities
    Health Care